# Zevalin-Containing Nonmyeloablative Conditioning for Stem Cell Transplantation (SCT)

> **NCT01490723** · PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 20 (actual)

## Conditions studied

- Leukemia
- Lymphoma

## Interventions

- **DRUG:** Rituximab
- **DRUG:** 111In Ibritumomab
- **PROCEDURE:** Planar Scintigraphy Imaging
- **DRUG:** 90Y IbritumomabTiuxetan
- **DRUG:** Fludarabine
- **DRUG:** Bendamustine
- **DRUG:** Thymoglobulin
- **DRUG:** Tacrolimus
- **DRUG:** Methotrexate
- **DRUG:** Mycophenolate
- **DRUG:** G-CSF
- **PROCEDURE:** Stem Cell Transplantation

## Key facts

- **NCT ID:** NCT01490723
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-01
- **Primary completion:** 2019-04-24
- **Final completion:** 2019-04-24
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2020-05-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01490723

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01490723, "Zevalin-Containing Nonmyeloablative Conditioning for Stem Cell Transplantation (SCT)". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01490723. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*